Stock Under $10 with 50-100% upside potential - 14 Days FREE!

7 Dividend Stocks That Want to Pay You More Money

Stock quotes in this article: TJX, ABT, CMCSA, ALL, ADI, PEG, SHW 

Abbott Labs

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Diversified pharmaceutical firm Abbott Labs (ABT), another of 2012's "Dividend Opportunity" stocks, is another name that hiked its payouts last week, ratcheting its dividend by 6.25% to 51 cents per share. That's a 3.62% yield at current levels.

While Abbott generates the majority of its sales though pharmaceuticals, the firm's exposure to medical devices and nutritional products makes the firm much more diversified than most of its peers. In a time where patent drop-offs are scaring investors away from big pharma more than ever before, Abbott's exposure to side businesses should look especially attractive.

That won't be the case for long, though -- Abbott is planning on splitting its pharmaceutical arm off from its health-care business. The move should squeeze some added returns out of the business at the risk of much more concentrated sector risk.

That said, the risks are a moot point for shareholders who own Abbott now; they will get shares of both companies.

On the other hand, current shareholders will also get to benefit from the value that's unlocked from the deal. In a market where valuations are under pressure, a sum-of-the-parts valuation is often less attractive than breaking businesses up. The move will boost margins at the pharmaceutical arm and make it more directly comparable with big pharma peers.

Ample balance sheet liquidity should keep dividends rolling for ABT shareholders.

In the fourth quarter, Fortress Investment Group initiated a new position in Abbott, which is also one of Ken Fisher's top holdings.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs